{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Buffered+Saline&page=6", "query": { "intervention": "Buffered Saline", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 239, "total_pages": 24, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Buffered+Saline&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Buffered+Saline&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T10:35:41.590Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01915212", "title": "Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "HSV529", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 69, "start_date": "2013-09-26", "completion_date": "2017-03-06", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-11-15T10:35:41.590Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01915212" }, { "nct_id": "NCT03682120", "title": "Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Avian Influenza", "Influenza Immunisation" ], "interventions": [ { "name": "A/H7N9", "type": "BIOLOGICAL" }, { "name": "MF59", "type": "DRUG" }, { "name": "Phosphate Buffered Saline (PBS) diluent", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 372, "start_date": "2018-11-02", "completion_date": "2020-04-30", "has_results": true, "last_update_posted_date": "2021-05-17", "last_synced_at": "2026-11-15T10:35:41.590Z", "location_count": 7, "location_summary": "Birmingham, Alabama • St Louis, Missouri • Cincinnati, Ohio + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Galveston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03682120" }, { "nct_id": "NCT05346302", "title": "Persistent Readiness Through Early Prediction Immunization Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Inflammatory Response" ], "interventions": [ { "name": "Pneumovax 23", "type": "DRUG" }, { "name": "Typhim VI", "type": "DRUG" }, { "name": "Saline", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Texas A&M University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 249, "start_date": "2022-02-08", "completion_date": "2022-12-21", "has_results": false, "last_update_posted_date": "2023-02-14", "last_synced_at": "2026-11-15T10:35:41.590Z", "location_count": 1, "location_summary": "College Station, Texas", "locations": [ { "city": "College Station", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05346302" }, { "nct_id": "NCT04801420", "title": "Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lyme Borreliosis" ], "interventions": [ { "name": "VLA15", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "5 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "5 Years to 65 Years" }, "enrollment_count": 625, "start_date": "2021-03-08", "completion_date": "2025-07-02", "has_results": true, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-11-15T10:35:41.590Z", "location_count": 19, "location_summary": "Bridgeport, Connecticut • Stamford, Connecticut • Waterbury, Connecticut + 12 more", "locations": [ { "city": "Bridgeport", "state": "Connecticut" }, { "city": "Stamford", "state": "Connecticut" }, { "city": "Waterbury", "state": "Connecticut" }, { "city": "Waterbury", "state": "Connecticut" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04801420" }, { "nct_id": "NCT01396239", "title": "Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Duchenne Muscular Dystrophy" ], "interventions": [ { "name": "AVI-4658 (Eteplirsen)", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Sarepta Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": "13 Years", "sex": "MALE", "summary": "7 Years to 13 Years · Male only" }, "enrollment_count": 12, "start_date": "2011-07", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2020-03-30", "last_synced_at": "2026-11-15T10:35:41.590Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01396239" }, { "nct_id": "NCT00270218", "title": "Safety of and Immune Response to Two Different HIV Vaccines, Each Followed by a Adenoviral Vaccine Boost, in HIV Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "VRC-HIVADV014-00-VP", "type": "BIOLOGICAL" }, { "name": "VRC-HIVDNA009-00-VP", "type": "BIOLOGICAL" }, { "name": "FFB", "type": "BIOLOGICAL" }, { "name": "PBS", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 66, "start_date": "2006-02", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2021-10-14", "last_synced_at": "2026-11-15T10:35:41.590Z", "location_count": 7, "location_summary": "Birmingham, Alabama • San Francisco, California • New York, New York + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00270218" }, { "nct_id": "NCT03275389", "title": "A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza, Human" ], "interventions": [ { "name": "D-SUIV cH8/1N1+AS03", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH5/1N1+AS03", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH11/1N1+AS03", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH8/1N1+AS01", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH5/1N1+AS01", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH11/1N1+AS01", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH8/1N1", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH5/1N1", "type": "BIOLOGICAL" }, { "name": "D-SUIV cH11/1N1", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Fluarix Quadrivalent", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "18 Years to 39 Years" }, "enrollment_count": 470, "start_date": "2017-09-08", "completion_date": "2020-03-26", "has_results": true, "last_update_posted_date": "2021-05-07", "last_synced_at": "2026-11-15T10:35:41.590Z", "location_count": 5, "location_summary": "South Miami, Florida • Wichita, Kansas • Rochester, New York + 2 more", "locations": [ { "city": "South Miami", "state": "Florida" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Rochester", "state": "New York" }, { "city": "Austin", "state": "Texas" }, { "city": "Norfolk", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03275389" }, { "nct_id": "NCT03591874", "title": "Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Graft Versus Host Disease", "Ocular Surface Disease", "oGVHD", "Ocular Graft vs Host Disease", "Brimonidine Tartrate", "Lubricant Eye Drops", "Ophthalmic Solutions", "Graft vs Host Disease" ], "interventions": [ { "name": "Brimonidine Tartrate", "type": "DRUG" }, { "name": "Placebos", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ocugen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2018-12-23", "completion_date": "2020-04-30", "has_results": true, "last_update_posted_date": "2022-07-06", "last_synced_at": "2026-11-15T10:35:41.590Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Palo Alto, California • Atlanta, Georgia + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Prairie Village", "state": "Kansas" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03591874" }, { "nct_id": "NCT00262080", "title": "Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hereditary Angioedema (HAE)" ], "interventions": [ { "name": "ecallantide", "type": "DRUG" }, { "name": "Phosphate Buffer Saline (PBS),", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": null, "sex": "ALL", "summary": "10 Years and older" }, "enrollment_count": 91, "start_date": "2005-12-31", "completion_date": "2007-02-28", "has_results": true, "last_update_posted_date": "2021-06-11", "last_synced_at": "2026-11-15T10:35:41.590Z", "location_count": 1, "location_summary": "Wheaton, Maryland", "locations": [ { "city": "Wheaton", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00262080" }, { "nct_id": "NCT05182749", "title": "Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Shigellosis" ], "interventions": [ { "name": "bacteriophage", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Intralytix, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 52, "start_date": "2023-02-23", "completion_date": "2025-09-30", "has_results": false, "last_update_posted_date": "2025-06-15", "last_synced_at": "2026-11-15T10:35:41.590Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05182749" } ] }